Trevi Therapeutics, Inc. TRVI Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Trevi Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Trevi Therapeutics, Inc.'s cash & equivalents?
- Trevi Therapeutics, Inc. (TRVI) reported cash & equivalents of $19.41M in Q1 2026.
- How has Trevi Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Trevi Therapeutics, Inc.'s cash & equivalents increased by 0.2% year-over-year, from $19.37M to $19.41M.
- What is the long-term trend for Trevi Therapeutics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Trevi Therapeutics, Inc.'s cash & equivalents has grown at a -15.9% compound annual growth rate (CAGR), from $45M to $18.91M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.